Efficacy and safety of SGLT-2 inhibitors in patients with comorbid type 2 diabetes and atrial fibrillation: A meta-analysis
Authors' conclusion
These findings confirm that SGLT-2i provides clinically meaningful benefits in T2DM patients with AF, demonstrating both efficacy and safety.
Study context
- Population
- Patients with T2D and atrial fibrillation (AF)10 studies (1 RCT, 9 cohort)
- Participants
- 44,559 patients
- Comparison
- SGLT2i vs control
- Outcome
- Efficacy outcomes
Methodological details6 electronic databases searched to 03 Jan 2025, subgroup analyses by region, control intervention and study design
- 6 electronic databases searched to 03 Jan 2025
- Subgroup analyses by region, control intervention and study design
Pooled result
As reported in the abstract
Estimate (95 % CI)P value
SGLT-2ivs Control
RR (ischemic stroke) 0.74(0.62–0.87)
P = 0.0004SGLT-2ivs Control
RR (CV mortality) 0.60(0.46–0.79)
P = 0.0003SGLT-2ivs Control
RR (hospitalization for HF) 0.55(0.48–0.63)
P < 0.001SGLT-2ivs Control
RR (all-cause mortality) 0.41(0.26–0.65)
P = 0.0001Between SGLT-2i and Control
RR (MI) 0.97(0.75–1.26)
P = 0.85Further pooled results
Subgroup analyses by region, control intervention and study design
- Results largely consistent with the primary analysis
Safety
| Outcome | RR (95 % CI) | P value | |
|---|---|---|---|
| Adverse drug events | 0.79 (0.39–1.60) | P = 0.51 | |
| 0.20.5125Relative risk (log scale) |
Original publication
Efficacy and safety of SGLT-2 inhibitors in patients with comorbid type 2 diabetes and atrial fibrillation: A meta-analysis. Diabetes Res Clin Pract. Published 6 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →